Pentagon mandates testosterone screening for men over 30, symptom checks for women
The Pentagon has issued new, immediate clinical guidelines instituting mandatory testosterone screening for male service members aged 30 and older, to be integrated into regular health assessments, with younger men tested only on request or if symptoms arise. While men face mandatory testing, women are not subject to routine testosterone blood tests; instead, clinicians will screen female service members for symptoms such as fatigue and menstrual disruptions linked to low-energy availability and related conditions, with limited off-label testosterone use for certain postmenopausal cases. The guidance also outlines imaging pathways for treatment, including follow-up screening and possible testosterone replacement therapy for those diagnosed with hypogonadism, as part of efforts to improve readiness and health. The Defense Department emphasizes a uniform approach to both genders and notes the FDA will hold a mid-September meeting to discuss testosterone use, underscoring ongoing medical debate. Some physicians have criticized universal screening as lacking solid evidence of improving combat readiness and potentially risking unnecessary treatment. The policy, effective immediately, signals a broader push to address hormonal and energy-related health issues among troops, while prompting questions about clinical value and safety.
